Business Context and Reporting Period
This Form 8-K filing by Evolent Health, Inc. (Delaware) was submitted on April 10, 2019, reporting events occurring on April 8, 2019. The filing addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and audit firm transitions.
Material Changes
- Dismissal of Previous Auditor: The Audit Committee dismissed PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm, effective immediately on April 8, 2019.
- Appointment of New Auditor: Deloitte & Touche LLP (Deloitte) was appointed to audit the consolidated financial statements for the year ending December 31, 2019.
- Audit History: PwC's audit reports for the years ended December 31, 2018, and 2017, were unqualified and contained no adverse opinions or disclaimers.
Management Commentary, Risks, and Contingencies
- Disagreements: The Company reported no disagreements with PwC regarding accounting principles, practices, financial statement disclosure, or auditing scope during the two most recent fiscal years and the subsequent interim period.
- Reportable Events: The only reportable event identified was a material weakness in internal control over financial reporting related to insufficient resources with appropriate accounting knowledge for complex transactions. The Company states this weakness was remediated as described in its Form 10-Q for the period ended June 30, 2018.
- Consultations: The Company confirmed it did not consult with Deloitte regarding accounting principles or audit opinions prior to their appointment.
Investor Verification Checklist
- Verify the content of the letter from PwC (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Review the Company's Form 10-Q for the period ended June 30, 2018, to confirm the details of the remediation of the previously disclosed material weakness in internal controls.
- Monitor future filings to ensure the transition to Deloitte proceeds without qualification or new reportable events.